Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
Key Highlights
- ➤Palvella management to present at Stifel 2026 Healthcare Conference November 10.
- ➤QTORIN rapamycin targets three rare vascular and skin conditions.
- ➤QTORIN pitavastatin targets disseminated superficial actinic porokeratosis.
- ➤Both product candidates remain investigational and lack FDA approval.
Expert Statements
Wes Kaupinen, Founder and CEO of Palvella Therapeutics
“Founded and led by rare disease biotech veterans”
WAYNE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that members of its management team will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026, at 9:20 a.m. ET.
A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay will be available for approximately 90 days following the event.
Get started
Create a free account to read the full story.